CSIMarket
 
Innate Pharma Sa  (NASDAQ: IPHA)
 

Innate Pharma Sa's Customers Performance

IPHA



 
IPHA's Source of Revenues During the corresponding time, Innate Pharma Sa saw a revenue deteriorated by -55.25 % year on year, While revenue at the Innate Pharma Sa's corporate clients

List of IPHA Customers




for the same period Innate Pharma Sa revnue deteriorated by -55.25 % year on year,

List of IPHA Customers

Innate Pharma Sa's Business Units
Proceeds from collaboration and licensing agreements    6.89 % of total Revenue
of which monalizumab agreement - AstraZeneca    2.44 % of total Revenue
of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program    4.44 % of total Revenue
of which Takeda agreement 2023    18.5 % of total Revenue
Others    5.56 % of total Revenue






Innate Pharma Sa's Comment on Sales, Marketing and Customers



Innate Pharma's customers include physicians, healthcare providers, and other entities subject to federal and state laws concerning fraud and abuse, anti-kickback statutes, false claims, transparency, and patient data privacy. The company conducts clinical studies in the European Union and processes personal health data in compliance with the General Data Protection Regulation (GDPR) and UK GDPR. These regulations govern the collection, use, processing, and transfer of personal information, including requirements for legal bases for processing, data security, data processing agreements, and reporting of security breaches.





Innate Pharma Sa’s Comment on Sales, Marketing and Customers


Innate Pharma's customers include physicians, healthcare providers, and other entities subject to federal and state laws concerning fraud and abuse, anti-kickback statutes, false claims, transparency, and patient data privacy. The company conducts clinical studies in the European Union and processes personal health data in compliance with the General Data Protection Regulation (GDPR) and UK GDPR. These regulations govern the collection, use, processing, and transfer of personal information, including requirements for legal bases for processing, data security, data processing agreements, and reporting of security breaches.








IPHA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Innate Pharma Sa 0.00 10.09 -55.08 181
SUBTOTAL 0.00 0.00 0.00 -

Sources: Innate Pharma Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Innate Pharma Sa’s corporate clients.
For your research, we’ve provided 9 tables on Innate Pharma Sa corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.